South & Central America Colistin Market Analysis and Forecast by Size, Share, Growth, Trends 2034

The South and Central America Colistin Market size is expected to reach US$ 41.8 Million by 2034 from US$ 29.3 Million in 2025. The market is estimated to record a CAGR of 4.1% from 2026 to 2034.

Executive Summary and South and Central America Colistin Market Analysis:

The colistin market in South & Central America is witnessing growth due to the widespread and increasing burden of multidrug-resistant (MDR) Gram-negative infections in hospitals and livestock sectors, where colistin is essential as a last-resort antibiotic for managing bloodstream infections (BSI) and sepsis. According to the Pan American Health Organization (PAHO), the Antimicrobial Resistance Surveillance in Latin America and the Caribbean 2023 Report indicates 1 in 7 infections resistant to antibiotics, with carbapenem-resistant Enterobacterales rising by 8% from 2023 to 2024, driving the demand for colistin to treat lower respiratory tract infections (LRTI) and urinary tract infections (UTIs) in hospital pharmacies. In 2024, PAHO's ReLAVRA+ network-involving 19 Latin American countries-reported increased MDR Acinetobacter baumannii in 33 nations, emphasizing colistin's role in ventilator-associated pneumonia (VAP). In 2025, PAHO projections showed sustained resistance, contributing to the increased use of colistin to treat cystic fibrosis.

South & Central America Colistin Market: Strategic Insights

South and Central America Colistin Market Segmentation Analysis:

• By Formulation, the South and Central America Colistin Market is segmented into Injectables (IV or IM), Oral, Topical Formulations, and Inhalation Solutions. The Injectables (IV or IM) segment dominated the market in 2025.
• By Indication, the South and Central America Colistin Market is segmented into Human Health and Animal Health. The Human Health segment dominated the market in 2025.
• By Human Health, the South and Central America Colistin Market is segmented into Bloodstream Infections (BSI) and Sepsis Lower, Respiratory Tract Infections (LRTI), Urinary Tract Infections (UTIs), Central Nervous System Infections, Skin Infections, Cystic Fibrosis, Tracheobronchitis or VAP, Gastrointestinal Infections, and Bowel Decontamination. The Respiratory Tract Infections (LRTI) segment dominated the market in 2025.
• By Distribution Channel, the South and Central America Colistin Market is segmented into Hospital Pharmacy, Retail Pharmacy, Online Channel, and Other Distribution Channel. The Hospital Pharmacy segment dominated the market in 2025.

South & Central America Colistin Market Players Density: Understanding Its Impact on Business Dynamics

The South & Central America Colistin Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

South and Central America Colistin Market Outlook

Combining colistin with agents such as meropenem, tigecycline, or fosfomycin can achieve synergy, improving microbial eradication and reducing mortality. For instance, in carbapenem-resistant Enterobacterales (CRE) infections, colistin-fosfomycin combinations showed superior outcomes compared to colistin alone. In critically ill patients with MDR Acinetobacter baumannii pneumonia, tigecycline–colistin combinations achieved a 47–48% clinical success rate, similar across groups but with better synergy in vitro. Synergy testing using checkerboard assays showed interactions in 75% of cases via Fractional Inhibitory Concentration Index, 50% via Loewe Additivity, and 41.6% via Bliss Independence for colistin with clindamycin, chloramphenicol, or minocycline. In a study of MDR Pseudomonas aeruginosa, 93.8% of colistin recipients were on combinations, with no significant mortality difference, but highlighting de-escalation. This trend is supported by microbiological studies showing synergy in all colistin-rifampicin combinations and 67% with carbapenems, contrasting preliminary human data but indicating potential for optimized regimens. As MDR infections increase globally, combinations could extend colistin's utility, fostering research and development collaborations and portfolio diversification in the pharmaceutical sectors. Thus, the increasing utilization of colistin in combination therapies to enhance efficacy against multidrug-resistant (MDR) and extensively drug-resistant (XDR) Gram-negative infections, addressing limitations of monotherapy such as emerging resistance, creates market opportunities.

South and Central America Colistin Market Country Insights

By country, the South and Central America Colistin Market is segmented into Brazil and the Rest of South and Central America. The Rest of South and Central America held the largest share in 2025.

Chile, Colombia, Peru, Cuba, Venezuela, and Bolivia are among the major countries contributing to the colistin market in the Rest of South & Central America. The market is growing due to a high prevalence of multidrug-resistant (MDR) Gram-negative infections across the region, where colistin is vital for managing bloodstream infections (BSI) and sepsis in hospitals and animal health. According to the Pan American Health Organization (PAHO), the Antimicrobial Resistance Surveillance in Latin America and the Caribbean 2023 Report indicates 1 in 7 infections resistant to antibiotics, with carbapenem-resistant Enterobacterales rising by 8% from 2023 to 2024, driving colistin demand for lower respiratory tract infections (LRTI) and urinary tract infections (UTIs). In 2024, PAHO's ReLAVRA+ network, involving 19 Latin American countries, reported increased MDR Acinetobacter baumannii and emphasized colistin's role in ventilator-associated pneumonia (VAP). Additionally, PAHO's 2025 AMR Action Plan supports oral formulations for animal health gastrointestinal infections via retail pharmacies, addressing central nervous system infections with bowel decontamination.

South and Central America Colistin Market Company Profiles

Some of the key players operating in the market include Livzon Pharmaceutical Group Inc, TZF Polfa S.A., Tecoland Corporation, Fujian Lifecome Biochemistry Limited, Zhejiang Shenghua Biok Chemical Company Limited, Xellia Pharmaceuticals ApS, Shandong LuKang Pharmaceutical Co., Ltd, Apeloa Pharmaceutical Co., Ltd., Norma Hellas S.A, and Hebei Shengxue Dacheng Pharmaceutical Co., Ltd.

These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.

South and Central America Colistin Market Research Methodology

The following methodology has been followed for the collection and analysis of data presented in this report:

Secondary Research

The research process begins with comprehensive secondary research, utilizing internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:

• Company websites, annual reports, financial statements, broker analyses, and investor presentations
• Industry trade journals and other relevant publications
• Government documents, statistical databases, and market reports
• News articles, press releases, and webcasts specific to companies operating in the market

Note: All financial data included in the Company Profiles section has been standardized to US$. For companies reporting in other currencies, figures have been converted to US$ using the relevant exchange rates for the corresponding year.

Primary Research

The Insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis and gain valuable insights. These research interviews are designed to:

• Validate and refine findings from secondary research
• Enhance the expertise and market understanding of the analysis team
• Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects

Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:

• Industry stakeholders: Vice Presidents, Business Development Managers, Market Intelligence Managers, and National Sales Managers
• External experts: Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise